Rush University Medical Center Sells AMPYRA(R) Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
Business Wire - Tue Aug 12, 7:01AM CDT
DRI Capital Inc. (DRI) and Rush University Medical Center (Rush) announced today that Drug Royalty III, a private equity fund managed by DRI has purchased Rush's royalties relating to worldwide sales of Ampyra(R) for approximately $42 million. Ampyra(R) (dalfampridine) extended release tablets, 10 mg, twice daily, were approved for use in the US in January 2010, and received conditional approval in Europe, where it is known as Fampyra(R), in July 2011. Ampyra is marketed by Acorda Therapeutics, Inc. (Acorda), within the United States, and by Acorda's licensee, Biogen IDEC, internationally.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 1.14%
Comtex SmarTrend(R) - Mon Aug 11, 3:57PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.07 to a high of $327.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $319.32 on volume of 981,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Biogen Idec to Potentially Rebound after Yesterday's 1.14% Sell Off
Comtex SmarTrend(R) - Mon Aug 11, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.07 to a high of $327.44. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $319.32 on volume of 981,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Tech, Health Care Lead Q2 Earnings Beats
at Investor's Business Daily - Mon Aug 11, 12:12PM CDT
Health care and technology stocks have turned in the most Q2 earnings and revenue beats, while the telecom sector has lagged, Merrill Lynch says in a report. Nearly 50 health care companies have reported so far, Merrill Lynch said, and nearly 70%...
Biogen Idec Earnings In Retrospect: Down 4.0% in the Last 19 Days (BIIB)
Comtex SmarTrend(R) - Mon Aug 11, 11:23AM CDT
Two weeks ago on July 23rd, 2014 Biogen Idec (NASDAQ:BIIB) reported earnings and analysts, on average, expected earnings of $2.84 on sales of $2.2 billion. The company actually reported EPS of $3.49 on sales of $2.4 billion, beating EPS estimates by $0.65 and beating revenue estimates by $265.5 million. Since the company's report, shares of Biogen Idec have fallen from $337.60 to $324.05, representing a loss of 4.0% in the past 19 days.
Biotech Equities Technical Momentum -- InterMune, Biogen Idec, Insmed, Dendreon, and Alexion Pharma
PR Newswire - Mon Aug 11, 7:40AM CDT
The trading session on Friday, August 08, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,553.93, up 1.13% and the NASDAQ Composite closed at 4,370.90, up 0.83%. The S&P 500 finished the day 1.15% higher at 1,931.59. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 699.99, up 1.14%, and the index has advanced 4.73% in the previous three months. Investor-Edge has initiated coverage on the following equities: InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Insmed Inc. (NASDAQ: INSM), Dendreon Corp. (NASDAQ: DNDN), and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Free research on these five companies can be accessed at:
3 Biotech Stocks to End Q2 on a Winning Note - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 2:54PM CDT
The rebound was due to strong earnings reports, product approvals, and acquisitions and licensing deals.
The Launch of Five Immunomodulatory Therapies for Relapsing Forms of Multiple Sclerosis Will Contribute to 4 Percent Annual Growth of the Total Market from 2013 to 2023
PR Newswire - Thu Aug 07, 12:00PM CDT
Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's Lemtrada, will help drive total sales across the multiple sclerosis (MS) market in the United States, France, Germany, Italy, Spain, United Kingdom and Japan to over $20 billion in 2023, reflecting 4 percent annual growth from 2013. Of note, future generics and projected biosimilar competition will cause major-market sales to contract in the latter part of our study period from a 2018 peak of over $22 billion.
TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis, Reimbursed in Alberta
CNW Group - Thu Aug 07, 9:00AM CDT
Biogen Idec Canada announces today that Alberta Health will now reimburse TECFIDERATM (dimethyl fumarate) through the Alberta Drug Benefit List (DBL). TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Isis Pharmaceuticals Posts Narrower-Than-Expected Q2 Loss - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Aug 07, 8:10AM CDT
Isis Pharmaceuticals (ISIS) remains on track to deliver revenues of more than $160 million this year.
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
PR Newswire - Wed Aug 06, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results and highlights for the quarter ended June 30, 2014 and provided a summary of recent corporate highlights.
Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]
Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.
Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...
Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs
Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.